Across TCGA pan-cancer cohorts, LINC01098 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LINC01098 data layer compared with 21 for mass-spec protein.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LINC01098 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LINC01098 expression acts as an unfavorable survival marker.
LUAD and SARC are the cancer types where LINC01098 Mutation most reproducibly stratifies survival.